 Alice Weaver
Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 6 | 2025 | 617 | 1.590 |
Why?
| | Human papillomavirus 16 | 2 | 2024 | 36 | 1.360 |
Why?
| | Papillomavirus Infections | 3 | 2025 | 331 | 1.220 |
Why?
| | Career Choice | 3 | 2022 | 215 | 1.050 |
Why?
| | Carcinoma, Squamous Cell | 5 | 2017 | 683 | 0.880 |
Why?
| | Salivary Gland Neoplasms | 1 | 2023 | 41 | 0.790 |
Why?
| | Personnel Selection | 1 | 2019 | 78 | 0.600 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 917 | 0.560 |
Why?
| | Students, Medical | 2 | 2019 | 341 | 0.550 |
Why?
| | Fibroblast Growth Factor 1 | 1 | 2016 | 12 | 0.520 |
Why?
| | Receptor, Notch1 | 1 | 2016 | 64 | 0.500 |
Why?
| | Education, Medical, Graduate | 2 | 2022 | 481 | 0.500 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2016 | 62 | 0.500 |
Why?
| | Schools, Medical | 1 | 2017 | 146 | 0.490 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2015 | 99 | 0.470 |
Why?
| | Mouth Neoplasms | 1 | 2016 | 120 | 0.470 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2015 | 43 | 0.470 |
Why?
| | Calcium-Binding Proteins | 1 | 2016 | 218 | 0.470 |
Why?
| | Biomedical Research | 2 | 2022 | 689 | 0.460 |
Why?
| | Robotic Surgical Procedures | 1 | 2016 | 126 | 0.450 |
Why?
| | DNA Repair | 2 | 2015 | 230 | 0.450 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 117 | 0.430 |
Why?
| | Communication | 1 | 2019 | 874 | 0.420 |
Why?
| | Papillomaviridae | 2 | 2025 | 126 | 0.350 |
Why?
| | Curriculum | 1 | 2017 | 980 | 0.330 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1060 | 0.330 |
Why?
| | Internship and Residency | 1 | 2019 | 1131 | 0.310 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2024 | 12 | 0.220 |
Why?
| | Oncogene Proteins, Viral | 1 | 2024 | 23 | 0.220 |
Why?
| | Gene Fusion | 1 | 2023 | 27 | 0.200 |
Why?
| | Salivary Glands | 1 | 2023 | 33 | 0.200 |
Why?
| | Survival Analysis | 2 | 2016 | 1320 | 0.200 |
Why?
| | Cell Culture Techniques | 1 | 2025 | 363 | 0.200 |
Why?
| | Cancer Vaccines | 1 | 2024 | 173 | 0.200 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 210 | 0.190 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2015 | 455 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 218 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 558 | 0.180 |
Why?
| | Physicians | 2 | 2022 | 904 | 0.170 |
Why?
| | Repressor Proteins | 1 | 2024 | 425 | 0.170 |
Why?
| | Mice, Inbred NOD | 2 | 2023 | 601 | 0.150 |
Why?
| | Immunotherapy | 1 | 2023 | 647 | 0.140 |
Why?
| | Prognosis | 2 | 2016 | 4031 | 0.140 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3420 | 0.140 |
Why?
| | Alabama | 1 | 2017 | 34 | 0.140 |
Why?
| | Humans | 12 | 2025 | 137514 | 0.130 |
Why?
| | Female | 7 | 2024 | 73162 | 0.130 |
Why?
| | Cetuximab | 1 | 2017 | 95 | 0.130 |
Why?
| | Pyrazines | 1 | 2017 | 92 | 0.120 |
Why?
| | Biopsy, Needle | 1 | 2016 | 191 | 0.120 |
Why?
| | Comet Assay | 1 | 2015 | 16 | 0.120 |
Why?
| | Tumor Suppressor p53-Binding Protein 1 | 1 | 2015 | 13 | 0.120 |
Why?
| | Homologous Recombination | 1 | 2015 | 26 | 0.120 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 434 | 0.120 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 226 | 0.120 |
Why?
| | BRCA1 Protein | 1 | 2015 | 76 | 0.120 |
Why?
| | Chromosomes | 1 | 2015 | 108 | 0.120 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 256 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2016 | 690 | 0.110 |
Why?
| | Mice, SCID | 1 | 2015 | 367 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 510 | 0.110 |
Why?
| | Benzimidazoles | 1 | 2015 | 169 | 0.110 |
Why?
| | Middle Aged | 4 | 2024 | 33355 | 0.110 |
Why?
| | DNA, Viral | 1 | 2016 | 362 | 0.110 |
Why?
| | Universities | 1 | 2017 | 432 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2017 | 1402 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1324 | 0.100 |
Why?
| | Pyrazoles | 1 | 2017 | 427 | 0.100 |
Why?
| | Male | 5 | 2024 | 67718 | 0.100 |
Why?
| | Signal Transduction | 2 | 2016 | 5096 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1740 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 2064 | 0.090 |
Why?
| | Aged | 2 | 2024 | 23798 | 0.090 |
Why?
| | Histones | 1 | 2015 | 641 | 0.080 |
Why?
| | Neoplasms | 1 | 2024 | 2666 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2017 | 15628 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2014 | 1167 | 0.070 |
Why?
| | Adult | 2 | 2024 | 37821 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5139 | 0.070 |
Why?
| | Phenotype | 1 | 2015 | 3205 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 3439 | 0.070 |
Why?
| | Apoptosis | 1 | 2015 | 2557 | 0.060 |
Why?
| | Mice | 3 | 2023 | 17843 | 0.060 |
Why?
| | Cohort Studies | 1 | 2016 | 5730 | 0.060 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2025 | 20 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2145 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2025 | 240 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5772 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2017 | 10821 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 252 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2494 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2025 | 1185 | 0.050 |
Why?
| | Animals | 3 | 2023 | 37011 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2022 | 211 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 269 | 0.040 |
Why?
| | United States | 1 | 2016 | 14696 | 0.040 |
Why?
| | Checkpoint Kinase 2 | 1 | 2017 | 29 | 0.030 |
Why?
| | Checkpoint Kinase 1 | 1 | 2017 | 30 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 379 | 0.030 |
Why?
| | Myristoylated Alanine-Rich C Kinase Substrate | 1 | 2014 | 6 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2014 | 57 | 0.030 |
Why?
| | Molecular Mimicry | 1 | 2014 | 40 | 0.030 |
Why?
| | Radiation, Ionizing | 1 | 2014 | 81 | 0.030 |
Why?
| | Radiation Tolerance | 1 | 2014 | 98 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 420 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 868 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1241 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1122 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 869 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 414 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2014 | 708 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2146 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1762 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2901 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2482 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2014 | 937 | 0.020 |
Why?
| | Mutation | 1 | 2014 | 3964 | 0.010 |
Why?
|
|
Weaver's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|